Hypercell Technologies

Industry: Therapeutics for swine flu

Drawing on exclusive technology and research, Hypercell Technologies identifies high-affinity monoclonal antibodies (MAbs) that offer protection against infectious respiratory diseases, particularly in swine. 
As of early 2016, the company was focusing on swine influenza and porcine reproductive and respiratory syndrome (PRRS). These common diseases are costly for the U.S. swine industry; swine flu costs producers around $10 per hog and $300 million per year. Current vaccines are not fully effective because they can’t protect against all possible flu strains, and it takes at least three weeks for the animal to develop immunity after receiving the shot.
Hypercell Technologies also plans to develop MAb vaccines for other infectious and immunodeficiency diseases in animals, offering significant economic benefits to swine and cattle producers and reducing food costs for the consumer.

Back to companies